Gilead Sciences, Inc.
NEWS
To ask the question, “What are the top biotech stocks?” is to get trapped in a maze of definitions: small cap versus large cap, upcoming catalysts, trending, or a byzantine series of technical evaluations. Rather than to attempt an overall view, here are a variety of biotech stocks that are worth a look this month for different reasons.
Many of the trends that affect biopharma recruitment are trends that affect healthcare in general, as well as other industries.
The two companies will use Verity’s Immunoscape platform to profile the molecular characteristics of inflammatory diseases.
Bill Gates via The Bill and Melinda Gates Foundation and Google co-founder Larry Page, have pledged $12 million to research to develop a universal flu vaccine. However, they aren’t the only tech billionaires to get into funding healthcare and life science research initiatives.
At the end of 2016, there were an estimated 36.7 million people living with HIV across the globe. With a large and growing patient population, the market for HIV treatments is expected to grow to $22.5 billion by 2025.
Shares of SteadyMed Ltd. have skyrocketed more than 77 percent in premarket trading today after United Therapeutics announced it will acquire the company for a total of $216 million, including $75 million in contingent consideration.
During the 2016 U.S. presidential election, the push for lower drug prices became one of the hot-button topics. Now there appears to be some efforts by advocacy groups and government entities to tackle the subject in several different ways.
It may not seem like it, but biotech stocks are actually up over the past year. The iShares Nasdaq Biotechnology ETF (IBB) is up about 4%--nothing to write home about, but hardly a disastrous performance.
A nonprofit organization, Knowledge Ecology International (KEI), recently filed a lawsuit against the National Institutes of Health (NIH) over Gilead Sciences’ patents for a new chimeric antigen receptor T-cell (CAR-T) therapy.
JOBS
IN THE PRESS